Optimistic Outlook for Soleno Therapeutics: Potential Synergy of Vykat in Niche Market Segments
I'm PortAI, I can summarize articles.
Kate Dellorusso from LifeSci Capital maintains a Buy rating for Soleno Therapeutics with a $110 price target. The optimism is based on the potential synergy of Vykat in combination therapies, especially for patients with conditions like diabetes. Despite mixed trial results, there's hope for clearer insights by 2026. The focus on patient segmentation in Prader-Willi syndrome could benefit Soleno in niche markets.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments